(Q51129504)

30 March 2018

title

Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. (English)

1 reference

30 March 2018

1 reference

1 reference

head and neck carcinoma

1 reference

5

Wilko Weichert

1 reference

30 March 2018

author name string

Annette Affolter

1

1 reference

30 March 2018

Gerson Samosny

2

1 reference

30 March 2018

Anne-Sophie Heimes

3

1 reference

30 March 2018

Johanna Schneider

4

1 reference

30 March 2018

Albrecht Stenzinger

6

1 reference

30 March 2018

Katharina Sommer

7

1 reference

30 March 2018

Alexandra Jensen

8

1 reference

30 March 2018

Arnulf Mayer

9

1 reference

30 March 2018

Walburgis Brenner

10

1 reference

30 March 2018

Wolf J Mann

11

1 reference

30 March 2018

Jürgen Brieger

12

1 reference

30 March 2018

publication date

21 February 2017

1 reference

30 March 2018

published in

Head & Neck

1 reference

30 March 2018

volume

39

1 reference

30 March 2018

issue

4

1 reference

30 March 2018

page(s)

623-632

1 reference

30 March 2018

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

cites work

1 reference

Activation of mitogen-activated protein kinase extracellular signal-related kinase in head and neck squamous cell carcinomas after irradiation as part of a rescue mechanism.

21 January 2018

1 reference

Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer.

21 January 2018

1 reference

Molecular and biological properties of the vascular endothelial growth factor family of proteins

21 January 2018

1 reference

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

21 January 2018

1 reference

Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.

21 January 2018

1 reference

Molecular biologic characteristics of seven new cell lines of squamous cell carcinomas of the head and neck and comparison to fresh tumor tissue

21 January 2018

1 reference

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience

21 January 2018

1 reference

Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).

21 January 2018

1 reference

Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma.

21 January 2018

1 reference

EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer

21 January 2018

1 reference

Molecular targeting agents in the context of primary chemoradiation strategies

21 January 2018

1 reference

Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy

21 January 2018

1 reference

Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins

21 January 2018

1 reference

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

21 January 2018

1 reference

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer

21 January 2018

1 reference

SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation

21 January 2018

1 reference

Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation

21 January 2018

1 reference

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family

21 January 2018

1 reference

Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas

21 January 2018

1 reference

The role of Raf kinases in malignant transformation.

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Prognostic significance of EGF receptor expression in early glottic cancer

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HED.24557

1 reference

30 March 2018

1 reference

30 March 2018